Silicon Valley-based venture capital firm, Niremia Collective, is thrilled to announce the completion of its inaugural investment fund, "Niremia Collective Fund I, LP," at $22.5 million. This global fund aims to support innovative startups in the field of well-being technology with LPs including renowned domestic and international corporations and institutional investors, including Shionogi Pharmaceuticals, Mistletoe Venture Partners founded by investor Taizo Son, and MIXI Inc. The fund has invested in twelve well-being technology startups, including Feno, which offers AI-powered oral care services, TRIPP, a VR/XR wellness platform, and DeepWell, which specializes in mental health treatment using gaming.

​

Niremia Collective was founded by Naoko Okumoto, a seasoned investor, board member, and technology executive with a solid history of building successful business portfolios in Silicon Valley and Japan, and Nichol Bradford, the founder of Transformative Tech, the world's largest ecosystem in well-being technology. Transformative Tech comprises approximately 9,000 members across 72 countries, including startups, investors, universities, research institutions, and corporations.

​

The mission of Niremia Collective is to empower humans to build a better world by reaching greater possibilities in human wellbeing. We work with a collective of visionary start-ups, aligned investors, and Transformative Tech.

​

According to the think tank Global Wellness Institute, the market size is expected to reach approximately $5.6 trillion globally in 2022 and is projected to reach $8.5 trillion by 2027. Against this backdrop of market expansion, Niremia Collective aims to provide capital and management resources to high-growth well-being startups, and also focus on supporting companies entering the well-being market along with incubating new business ventures.

​

Taizo Son, Founder of Mistletoe:

​

"I was immediately impressed by their broad and deep network of innovators, which is the inspiration for their name 'Collective'. I am confident that Niremia Collective's unique perspective, expertise, and culture of mutual growth will create new value in the world."

​

Yosuke Miharu, Executive Officer and Head of Healthcare Strategy, Shionogi Pharmaceuticals:

​

"Shionogi is committed to creating the future of healthcare on new platforms, providing comprehensive solutions to patient and societal needs beyond just medication. We highly anticipate that our partnership with Niremia Collective will accelerate the development and delivery of innovative drugs and medical services to meet unmet needs worldwide. Together, we aim to build a better world in the healthcare field."

 

Note:  This release is intended for public disclosure of our activities and is not created for the purpose of investment solicitation. It does not constitute an offer to acquire any shares or other securities of the fund in Japan, the United States, or other regions. The information contained herein is true and accurate as of the date of publication but is subject to change without notice. This document may contain forward-looking statements based on certain assumptions, and actual results may significantly differ due to various known or unknown uncertainties and risks.